Skip to main content
. Author manuscript; available in PMC: 2023 May 1.
Published in final edited form as: Oncogene. 2022 Oct 12;41(46):5020–5031. doi: 10.1038/s41388-022-02491-8

Fig. 5. PARPi-resistant BRCA2-deficient cells increase fork protection via suppressing EZH2/MUS81 pathway.

Fig. 5.

(a) Fork stabilization was determined by DNA fiber assay as described in Materials and Methods. The schematic is shown above. Plots of IdU/CldU tract length ratios for individual replication forks in treated cells are shown below the schematic. (b) Western blotting of EZH2, MUS81, and GAPDH in cells with or without olaparib treatment. Densitometric values of EZH2 and MUS81 relative to GAPDH are shown. (c) Immunoblotting of EZH2 and MUS81 in cells transfected with or without siRNAs against EZH2 or MUS81. (d) DNA fiber assays were performed to study replication fork protection as mentioned in (a). CldU/IdU pulse-labeling followed by a 2-hour olaparib (20 μM) with or without silencing of EZH2 or MUS81. Dot plots of IdU to CldU tract length ratios for individual replication forks in treated cells are shown. *, p < 0.05; **, p < 0.01; ***, p < 0.001; ns, not significant.